Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

  • Revenue in USD (TTM)47.70bn
  • Net income in USD6.43bn
  • Incorporated1970
  • Employees74.00k
  • Location
    Merck & Co Inc2000 Galloping Hill RdKENILWORTH 07033-1310United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttp://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Acceleron Pharma IncDeal completed30 Sep 202130 Sep 2021Deal completed8.59%11.59bn
Pandion Therapeutics IncDeal completed25 Feb 202125 Feb 2021Deal completed9.35%1.81bn
Data delayed at least 15 minutes, as of Jan 18 2022 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.